Skip to main content
FDA Breakthrough Device Designation

The First Implantable Always-On EEG

Imagine never having to guess about your seizure activity again. The Ally 100 gives you and your doctor continuous, objective brain data — replacing uncertainty with clarity.

As featured inNatureIEEENeurology
0
days
Continuous Monitoring
0
min
Implant Procedure
0
Seizure Detection
0
/day
Cost Efficiency

The Problem: Patients Are Stuck

If you've ever struggled to remember when your last seizure happened, or felt frustrated that your doctor only sees a snapshot of your brain — you're not alone. 98% of seizure data today relies on memory alone.

60% of seizures go missed or unreported
Current EEG studies limited to hours or days
No reliable objective biometric for epilepsy exists
Under-treated seizures increase risk of sudden death

The Solution: Ally 100

Instead of asking "How have you been feeling?" your doctor will know exactly what's been happening — 24/7, for up to 3 years.

Automated seizure detection around the clock
1,095 days of continuous monitoring
Minimally invasive 15-minute procedure
Gold-standard EEG accuracy at fraction of cost

Seamless Outpatient Procedure

A simple outpatient procedure. Then your brain data works for you — automatically, continuously, for years.

01

Implant

15-minute minimally invasive procedure under local anesthesia at ambulatory surgery center

02

Monitor

Device continuously records EEG data subcutaneously with moderate to high signal resolution

03

Transmit

Data wirelessly transmitted to patient's smartphone and uploaded to secure cloud

04

Analyze

AI/ML algorithms detect seizures, predict episodes, and provide actionable insights

Gold-Standard Accuracy at a Fraction of the Cost

FeatureNVT (Ally 100)Routine EEGVideo EEGIntracranial
Duration~1,095 days1 hour3-7 days5-7 days
LocationAnywhereOfficeHospitalICU/EMU
InvasivenessMinimalNon-invasiveNon-invasiveHighly invasive
Cost per Day~$20$500/study~$9,000/day>$9,000/day
Seizure DetectionVery HighVery LowMod. LowHigh

The Only Minimally Invasive Brain Computer Interface

FeatureNVTWearablesInvasive BCI
Fully Implanted
Chronic Monitoring
General Purpose
Low Risk / Low Cost
Scalable / Compliant

Pathway to FDA Approval

We're on an accelerated path to bring this technology to patients who need it most.

Accomplished

Human Proof of Concept

Over 150 patients validated high sensitivity and specificity

Accomplished

Canine Implants

Successful pre-clinical canine implants with reliable data transmission

Accomplished

FDA Pre-IDE Meeting

De novo pathway with low approval bar granted

Next Step

FDA Approval

First objective seizure burden biometric approval

Frequently Asked Questions

Answers to common questions about the Ally 100 and continuous brain monitoring.

What is the NeuroView Ally 100?+

The Ally 100 is the world's first minimally invasive, always-on EEG implant designed for continuous seizure monitoring in epilepsy patients. It records brain activity 24/7 for up to 1,095 days (3 years) and transmits data wirelessly to a smartphone app.

How is the Ally 100 implanted?+

The Ally 100 is implanted through a 15-minute minimally invasive outpatient procedure under local anesthesia. The device is placed subcutaneously (under the skin) on the skull, requiring no brain surgery. Patients can go home the same day.

How much does continuous brain monitoring cost compared to hospital EEG?+

The Ally 100 costs approximately $20 per day of monitoring, compared to over $9,000 per day for inpatient video EEG monitoring. Over its 3-year lifespan, it provides continuous data at a fraction of the cost of even a single hospital stay.

Can the Ally 100 predict seizures before they happen?+

Yes. The Ally 100's AI algorithms analyze continuous EEG patterns to identify pre-seizure biomarkers, providing patients and clinicians with early warning predictions. Clinical data shows the system can detect seizure risk hours before an event occurs.

Does NeuroView have FDA approval?+

NeuroView Technology has received FDA Breakthrough Device Designation, which provides an accelerated pathway to approval. The company has completed human proof-of-concept studies with over 150 patients and successful pre-clinical canine implants.

Who is a candidate for the Ally 100?+

The Ally 100 is designed for patients with epilepsy who need continuous seizure monitoring, particularly those with drug-resistant epilepsy, patients being evaluated for surgery, or those whose seizure frequency is difficult to quantify with traditional methods.

Want to Learn More?

Whether you're a patient exploring options or a physician seeking better tools — we're here to help.